Navigation Links
Humacyte Presents Interim First-in-Human Data For Investigational Bioengineered Blood Vessel at the American Heart Association (AHA) Scientific Sessions 2013
Date:11/20/2013

RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2013 /PRNewswire/ -- Humacyte, Inc., a pioneer in regenerative medicine, today announced the presentation of interim, first-in-human data from an ongoing, multi-center study in Poland, evaluating the company's investigational bioengineered blood vessel in hemodialysis patients with End-Stage Renal Disease (ESRD). The data were presented by Dr. Jeffrey H. Lawson, M.D., Ph.D., at the American Heart Association Scientific Sessions 2013 in Dallas, Texas (abstract). Dr. Lawson is Professor of Surgery and Pathology with tenure at Duke University Medical Center (Durham, North Carolina, USA), and Director of the Vascular Research Laboratory and Director of Clinical Trials for the Department of Surgery. He is also Clinical Consultant to Humacyte.

This is the first time surgical data from patients have been reported for the Humacyte investigational bioengineered vessel; the interim data come from a cohort of 28 study participants out of a total of 30 that will ultimately be enrolled in the three-site study in Poland (http://clinicaltrials.gov/show/NCT01744418%20CLN-PRO-V001%20NCT01744418). The first patients were implanted with the investigational vessels in December, 2012, and the vessels were first used for hemodialysis in February, 2013. The primary endpoints of the study in Poland are safety, tolerability, and patency to be examined at each visit within the first six months after graft implantation. Patients will be followed for an additional
'/>"/>

SOURCE Humacyte, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
3. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
4. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
5. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
9. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
10. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
11. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  Heated dialogue in recent months about ... cancer treatments to Gilead,s new hepatitis C drug Harvoni® ... world questioning what it means to put a price ... And while drug pricing is one of the ... both a general business and ethical standpoint – it ...
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... , Chief Executive Officer, will be presenting at the 26 ... York Palace Hotel in New York . ... at 2:00 PM ET. In addition, Mr. Krakauer and ... for separate one-on-one meetings during the day. ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
... IRIDEX Corporation (NASDAQ: IRIX ) today announced that it ... after the market closes on Thursday, March 1, 2012. ... a conference call with the investment community at 5:00 ... 2012 to discuss the results of the quarter and ...
... Medical Corp.,s (Nasdaq Market: ESMC) subsidiary,  Sonomed Escalon™ announced ... AXIS™ Image Management System at the recent World Ophthalmology ... Matthew Carnevale, Chief Technical Officer, stated that ... ophthalmic diagnostic imaging management, and provides an entirely new ...
Cached Medicine Technology:Sonomed Escalon™ Announces Release of AXIS™ iPad App 2Sonomed Escalon™ Announces Release of AXIS™ iPad App 3
(Date:11/22/2014)... is an important company in the dress industry. The ... online market share by a series of promotions. Recently, it ... a bridesmaid dress promotion for the new year 2015. The ... dresses from this company are not only of high quality ... good at manufacturing wedding dresses. Customers prefer to choose the ...
(Date:11/22/2014)... to provide better services, LunaDress has updated its website with ... that a suitable cocktail party dress is crucial for every ... dresses supplier’s high quality items are offered at attracting prices, ... industry, LunaDress understands that it is not easy to provide ... the professional level and innovation ability. The growth of sales ...
(Date:11/22/2014)... Dallas, TX (PRWEB) November 22, 2014 ... Society (ICS) as the complaint that the individual ... times for voiding. The report “Nocturia – Pipeline ... therapeutic development for Nocturia, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:11/22/2014)... "My friend went in for a mammogram and ... an inventor from Cambria Heights, N.Y. "To add insult ... time because the first results were inaccurate. Her misfortune ... MAMO EASY to offer a more comfortable way to ... from the pain normally involved with this procedure. The ...
(Date:11/22/2014)... November 22, 2014 A petition seeking ... http://www.morcellatorlawsuit2015.com ) in minimally-invasive hysterectomies and fibroid removal ... the end of October, Bernstein Liebhard LLP reports. ... as of November 21st, 2014. That represents an increase ... had signed on to the campaign.* , The campaign ...
Breaking Medicine News(10 mins):Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4
... (HealthDay News) -- Children who are allergic to penicillin ... additional drug allergies, new research suggests. Pediatric patients ... authors noted. Prior research in adults has suggested that ... allergies to other medications. But in the new ...
... one Michigan State University professor will explore why in old ... whites. Prior research also shows of those 71 years ... mild cognitive impairment, or various types of mental processing problems, ... first to produce statistics about life expectancy with and without ...
... new study conducted by Boston University School of Medicine (BUSM) ... believe that chewing the plant khat is harmful to one,s ... The study, which is published online in the journal ... 2013 students Paul Yi, John Kim and Khalil Hussein. Richard ...
... warned that, in addition to causing obesity, eating too ... risk for colon cancer. Now, researchers at Temple University ... The findings, "Epigenetic Differences in Normal Colon Mucosa of ... in the March issue of the American Association for ...
... HIV-positive patient, one of her first questions is whether he ... response is about dead relatives or friends. "We talk about ... experience will be very different," said the infectious-disease specialist at ... "Yes it,s the same virus and could have the same ...
... - Researchers from Boston University School of Medicine (BUSM) ... with breast pain who receive imaging (mammograms, MRIs or ... diagnostic testing, but do not gain benefit from these ... Journal of General Internal Medicine. Breast pain ...
Cached Medicine News:Health News:Kids' Penicillin Allergy May Not Signal Other Drug Reactions 2Health News:New research will shed light on racial gap in dementia 2Health News:BUSM student-published study focuses on khat chewing in Yemeni culture 2Health News:Study shows how high-fat diets increase colon cancer risk 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 3Health News:Research finds little benefit of breast imaging tests for women with breast pain 2
For the quantitative determination of Inorganic Phosphorus in serum. Linearity: 12.0 mg/dl....
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
For the kinetic quantitative determination of g-Glutamyl Transferase in serum for manual and/or automated procedures....
Intended for the quantitative determination of alphaamylase activity in serum. Single vial, dry powder reagent. Reaction: Kinetic. Wavelength: 405 nm. Linearity: 2000 U/L at 37C....
Medicine Products: